The State of Myeloproliferative Neoplasms (MPNs)

Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms.

Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera.

Switching their focus to myelofibrosis, Rami Komrokji, MD, and Ruben Mesa, MD, consider mainstay treatment options in this setting.

Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Focusing on clinical trials and novel therapies, Rami Komrokji, MD, and Ruben Mesa, MD, share their hope for the future management of essential thrombocythemia and polycythemia vera.

Comprehensive discussion on the management of myelofibrosis, covering both monotherapy and combination therapy strategies.

Before closing out their program on myeloproliferative neoplasms, Rami Komrokji, MD, and Ruben Mesa, MD, discuss the potential for progression of MF to acute myeloid leukemia and highlight key treatment strategies.